Press release
Dry Age-related Macular Degeneration Pipeline Assessment - FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, Growth Prospects, and Key Companies by DelveInsight
Dry Age-related Macular Degeneration Pipeline
The report comprises Dry Age-related Macular Degeneration pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Dry Age-related Macular Degeneration therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Dry Age-related Macular Degeneration pipeline products.
Some of the key takeaways from the Dry Age-related Macular Degeneration Pipeline Report https://www.delveinsight.com/report-store/dry-age-macular-degeneration-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Companies across the globe are diligently working toward developing novel Dry Age-related Macular Degeneration treatment therapies with a considerable amount of success over the years.
Dry Age-related Macular Degeneration Key players such as - Alkeus Pharmaceuticals, Dobecure, Iveric Bio, Mitotech, Stealth BioTherapeutics, Allergo Ophthalmics, Gyroscope Therapeutics, Gemini Therapeutics, Luxa Biotechnology, CHABiotech CO., Ltd, Regenerative Patch Technologies, Lineage Cell Therapeutics, Janssen Research & Development, Belite Bio, Katairo, Cognition Therapeutics, Eye Co Pty Ltd, Applied Genetic Technologies Corporation (AGTC), Aviceda Therapeutics, Kodiak Sciences, Ascentage Pharma, OliX Pharmaceuticals, Nanoscope Therapeutics, Inc., Biophytis, Eyestem, Eyevensys, SanBio, Beta Therapeutics, MacRegen, Amarna Therapeutics, MeiraGTx, Cognition Therapeutics, Ocugen, Catalyst Biosciences, Endogena Therapeutics, Oculogenex, Clover Therapeutics, Retrotope, Stuart Therapeutics,and others, are developing therapies for the Dry Age-related Macular Degeneration treatment
Dry Age-related Macular Degeneration Emerging therapies such as - EYS809, Zimura, OLX301A, RPESC RPE 4W, GEM103, Risuteganib, GT005, ALK-001, CPCB-RPE1, and others are expected to have a significant impact on the Dry Age-related Macular Degeneration market in the coming years.
Based on Product Types, the Dry Age-related Macular Degeneration pipeline is broadly segmented into Mono and Combination therapies
In January 2016, IVERIC Bio initiated a Phase II/III study to evaluate the safety and efficacy of intravitreous administration of Zimura when administered in subjects with geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD)
In June 2020, IVERIC bio initiated a Phase III Multicenter, Randomized, Double Masked, Sham- ControlledClinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration. This study aims to evaluate the safety and efficacy of Zimura intravitreal administration in patients with geographic atrophy secondary to age-related macular degeneration (AMD). Patients will be randomized in 1:1 to the following monthly treatment groups: Zimura 2 mg and Sham.
In July 2021, IVERIC Bio received a written agreement from the US FDA under a Special Protocol Assessment for the overall design of GATHER2, the Company's pivotal clinical trial of Zimura (avacincaptad pegol) in development for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). GATHER2 is designed tobe an adequate and well-controlled clinical trial which, if positive, would support a New Drug Application (NDA) forZimura in the treatment of GA secondary to AMD
Dry Age-related Macular Degeneration Overview
Age-related macular degeneration (AMD) is a degenerative disease of the center area of the ocular-posterior segment (the Overview macula lutea) that causes slow degeneration in central vision and severe disability in affected persons. Clinically, Age-related macular degeneration is classified according to different approaches. One such approach is that the disease is classified as early- to late-stage (advanced AMD). Advanced Age-related macular degeneration is classified into the nonexudative or atrophic form (dry AMD) and the exudative or neovascular form (wet AMD).
The Age-related macular degeneration diagnostic methods include fundus imaging, fluorescein angiogenesis (FA), indocyanine green angiography (ICGA), optical coherence tomography (OCT), Optical coherence tomography angiography (OCTA), and artificial intelligence (AI). These techniques play an important role in the diagnosis of Age-related macular degeneration and have their unique advantages. A detailed understanding of the molecular mechanisms underlying wet AMD has led to several robust FDA-approved therapies. In contrast, there are no approved treatments for dry Age-related macular degeneration.
Learn more about the novel and emerging Dry Age-related Macular Degeneration pipeline therapies @ Dry Age-related Macular Degeneration Pipeline Analysis https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Dry Age-related Macular Degeneration Pipeline Therapies along with Key Players:
EYS809: Eyevensys
Zimura: IVERIC bio
OLX301A: OliX Pharmaceuticals
RPESC RPE 4W: Luxa Biotechnology
GEM103: Gemini Therapeutics
Risuteganib: Allegro Ophthalmics
GT005: Gyroscope Therapeutics
ALK-001: Alkeus Pharmaceuticals
CPCB-RPE1: Regenerative Patch Technologies
Dry Age-related Macular Degeneration Pipeline Analysis
The report provides insights into:
The report provides detailed insights about companies that are developing therapies for the Dry Age-related Macular Degeneration treatment with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dry Age-related Macular Degeneration Treatment.
Dry Age-related Macular Degeneration key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Dry Age-related Macular Degeneration Drugs are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dry Age-related Macular Degeneration market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Further Dry Age-related Macular Degeneration product details are provided in the report.
Download the Dry Age-related Macular Degeneration pipeline report to learn more about the emerging Dry Age-related Macular Degeneration therapies at: https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Scope of Dry Age-related Macular Degeneration Pipeline Drug Insight
Coverage: Global
Key Dry Age-related Macular Degeneration Companies: Alkeus Pharmaceuticals, Dobecure, Iveric Bio, Mitotech, Stealth BioTherapeutics, Allergo Ophthalmics, Gyroscope Therapeutics, Gemini Therapeutics, Luxa Biotechnology, CHABiotech CO., Ltd, Regenerative Patch Technologies, Lineage Cell Therapeutics, Janssen Research & Development, Belite Bio, Katairo, Cognition Therapeutics, Eye Co Pty Ltd, Applied Genetic Technologies Corporation (AGTC), Aviceda Therapeutics, Kodiak Sciences, Ascentage Pharma, OliX Pharmaceuticals, Nanoscope Therapeutics, Inc., Biophytis, Eyestem, Eyevensys, SanBio, Beta Therapeutics, MacRegen, Amarna Therapeutics, MeiraGTx, Cognition Therapeutics, Ocugen, Catalyst Biosciences, Endogena Therapeutics, Oculogenex, Clover Therapeutics, Retrotope, Stuart Therapeutics, and others
Key Dry Age-related Macular Degeneration Therapies: EYS809, Zimura, OLX301A, RPESC RPE 4W, GEM103, Risuteganib, GT005, ALK-001, CPCB-RPE1, and others
Dry Age-related Macular Degeneration Therapeutic Assessment: Dry Age-related Macular Degeneration current marketed and Dry Age-related Macular Degeneration emerging therapies
Dry Age-related Macular Degeneration Market Dynamics: Dry Age-related Macular Degeneration market drivers and Dry Age-related Macular Degeneration market barriers
Request for Sample PDF Report to know more about Dry Age-related Macular Degeneration Pipeline Assessment
https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1 Dry Age-related Macular Degeneration Report Introduction
2 Dry Age-related Macular Degeneration Executive Summary
3 Dry Age-related Macular Degeneration Overview
4 Dry Age-related Macular Degeneration- Analytical Perspective In-depth Commercial Assessment
5 Dry Age-related Macular Degeneration Pipeline Therapeutics
6 Dry Age-related Macular Degeneration Late Stage Products (Phase II/III)
7 Dry Age-related Macular Degeneration Mid Stage Products (Phase II)
8 Dry Age-related Macular Degeneration Early Stage Products (Phase I)
9 Dry Age-related Macular Degeneration Preclinical Stage Products
10 Dry Age-related Macular Degeneration Therapeutics Assessment
11 Dry Age-related Macular Degeneration Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Dry Age-related Macular Degeneration Key Companies
14 Dry Age-related Macular Degeneration Key Products
15 Dry Age-related Macular Degeneration Unmet Needs
16 Dry Age-related Macular Degeneration Market Drivers and Barriers
17 Dry Age-related Macular Degeneration Future Perspectives and Conclusion
18 Dry Age-related Macular Degeneration Analyst Views
19 Appendix
20 About DelveInsight
Dive deep into rich insights for Dry Age-related Macular Degeneration emerging therapies and assessment, visit @ Dry Age-related Macular Degeneration Pipeline and Emerging Therapies https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Trending Reports:
Diagnostic Imaging Equipment Market
https://www.delveinsight.com/report-store/diagnostic-imaging-equipment-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Diagnostic Imaging Equipment Market By Product (X-Ray Imaging Systems, Computed Tomography (CT) Scanners, Ultrasound Systems, Magnetic Resonance Imaging (MRI) Systems, Nuclear Imaging Systems, Mammography Systems, And Others), By Application (Cardiology, Oncology, Gastroenterology, Gynecology, And Other Applications), By End-User (Hospitals, Diagnostic Imaging Centres, And Others), by geography is expected to grow at a steady CAGR forecast till 2026 owing to rising technological advancement and increasing prevalence of chronic diseases.
Invasive Candidiasis Market
https://www.delveinsight.com/report-store/invasive-candidiasis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"DelveInsight's 'Invasive Candidiasis Market Insight, Competitive Landscape and Market Forecast, 2027' report delivers an in-depth understanding of Invasive Candidiasis and the historical and forecasted Invasive Candidiasis market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Sialidosis Market
https://www.delveinsight.com/report-store/sialidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Sialidosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Sialidosis, historical and forecasted epidemiology, and the Sialidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Filgrastim Biosimilar Insight
https://www.delveinsight.com/report-store/filgrastim-biosimilar-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's, "Filgrastim Biosimilar Insight, 2022," report provides comprehensive insights about 20+ companies and 20+ marketed and pipeline drugs in the Filgrastim Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Pain Management Devices Market
https://www.delveinsight.com/report-store/pain-management-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Pain Management Devices Market By Type Of Devices (Neuromodulation & Neurostimulation Devices, Analgesic Infusion Pumps [Intrathecal Infusion Pumps and External Infusion Pumps], Ablation Devices [Radiofrequency Ablation Devices And Cryoablation Devices], And Others), By Application (Neuropathic Pain, Cancer Pain, Facial & Migraine Pain, Musculoskeletal Pain, and Others), By Geography is expected to grow at a steady CAGR Forecast till 2027
To know more about our Competitive Services, Click here:
https://www.delveinsight.com/consulting/competitive-intelligence-services?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Dry Age-related Macular Degeneration Pipeline Assessment - FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, Growth Prospects, and Key Companies by DelveInsight here
News-ID: 2724095 • Views: …
More Releases from DelveInsight Business Research
Global Pharmaceutical Cartridges Market to grow at a CAGR of 7.39% to reach USD …
According to DelveInsight's analysis, The growth of the pharmaceutical cartridges market is largely fueled by the increasing prevalence of chronic diseases that require long-term and consistent medication use. Moreover, the rising trend of self-administered treatments and the growing preference for home-based healthcare are major contributors to market expansion. Technological advancements in drug delivery systems have further supported this growth by enhancing patient convenience, improving dosage precision, and promoting better treatment…
Global Nucleic Acid Amplification Testing Market to grow at a CAGR of 8.13% by 2 …
According to DelveInsight's analysis, The growing demand for Nucleic Acid Amplification Testing (NAAT) is primarily driven by the increasing prevalence of infectious and genetic diseases. Additionally, the rising incidence of cancer and the expanding R&D efforts by major industry players are further fueling market growth. Together, these factors are expected to support a strong upward trajectory for the NAAT market throughout the forecast period from 2025 to 2032.
DelveInsight's "Nucleic Acid…
Global Cardiac Mapping System Market to grow at a CAGR of 8.37% by 2032, Evaluat …
According to DelveInsight's analysis, The growing incidence of cardiac arrhythmias, including atrial fibrillation and ventricular tachycardia, is driving the expansion of the cardiac mapping system market. These systems play a crucial role in the early detection and management of such conditions by providing real-time visualization of the heart's electrical activity, thereby reducing the risk of severe complications like stroke and heart failure. Moreover, the rising adoption of minimally invasive procedures,…
Global Graft Preparation System Market to grow at a CAGR of 4.17% to reach USD 3 …
According to DelveInsight's analysis, The demand for graft preparation systems is experiencing notable growth, primarily driven by the rising incidence of bone disorders and skin-related conditions. Moreover, the increasing number of surgical procedures worldwide, coupled with expanding R&D initiatives and strategic collaborations among leading market players, is further fueling market expansion. Together, these factors are expected to create a strong growth outlook for the graft preparation system market during the…
More Releases for Macular
2025-2034 Macular Edema and Macular Degeneration Market Roadmap: Insights for Co …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts
How Large Will the Macular Edema and Macular Degeneration Market Size By 2025?
In the past few years, the market size for macular edema and macular degeneration has seen significant growth. It is projected to increase from $9.65 billion in 2024 to $10.43 billion in 2025, exhibiting a compound…
Macular Edema and Macular Degeneration Market Poised for 7.1% Growth, Set to Hit …
How Are the key drivers contributing to the expansion of the macular edema and macular degeneration market?
The growth of the macular edema and macular degeneration market is predicted to be driven by the escalating number of individuals suffering from diabetes. Diabetes is a long-term health condition that results in elevated levels of glucose in the bloodstream. The condition harms the eye's blood vessels, potentially leading to macular edema and macular…
Macular Edema and Macular Degeneration Market Outlook 2025-2034: Key Trends, Gro …
"How Big Is the Macular Edema and Macular Degeneration Market Expected to Be, and What Will Its Growth Rate Be?
The macular edema and macular degeneration market has seen significant growth in recent years. It will expand from $9.65 billion in 2024 to $10.43 billion in 2025, with a CAGR of 8.1%. Factors contributing to this growth include the aging population, increasing diabetes prevalence, early diagnosis and awareness, global initiatives in…
Macular Edema and Macular Degeneration Market to Reach $22.51 Billion by 2034
The global macular edema and macular degeneration market, valued at $10.33 billion in 2023, is on track to grow at a remarkable compound annual growth rate (CAGR) of 7.34%, reaching $22.51 billion by 2034. This substantial market expansion is being fueled by rising treatment innovations, an increasing global prevalence of related diseases, and a surge in technological advancements in diagnostics and therapies.
Download White Paper: https://www.towardshealthcare.com/download-statistics/5375
Market Overview and Key Drivers
The macular…
Macular Edema and Macular Degeneration Market Size, Trends, Growth, Outlook 2024 …
"The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Macular Edema and Macular Degeneration Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $12.84…
Macular Edema and Macular Degeneration Market: Key Trends, Competitor Analysis, …
"Exploring the Global Macular Edema and Macular Degeneration Market: A Comprehensive Overview
Insights into Macular Edema and Macular Degeneration Market: Global Trends and Analysis
Macular Edema and Macular Degeneration Industry - Key Market Dynamics and Trends
The macular edema and macular degeneration market size has grown strongly in recent years. It will grow from $8.84 billion in 2023 to $9.65 billion in 2024 at a compound annual growth rate (CAGR) of 9.1%. The…
